Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$401.80 +2.4%	$318.24	$205.87 ▼ $402.43	$51.14B	0.25	1.03 million shs	1.78 million shs
ARGX argenex	$673.80 +0.5%	$571.11	$475.65 ▼ $689.13	$41.02B	0.39	414,608 shs	633,642 shs
REGN Regeneron Pharmaceuticals	$558.87 +2.5%	$538.05	$476.49 ▼ $1,211.20	$58.89B	0.33	858,977 shs	1.66 million shs
SBMFF Sino Biopharmaceutical	$0.95 +6.8%	$0.71	$0.34 ▼ $0.95	$17.87B	0.62	2,377 shs	100 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+2.44%	+22.20%	+21.84%	+54.90%	+69.21%
ARGX argenex	+0.52%	+13.82%	+23.61%	+3.71%	+30.61%
REGN Regeneron Pharmaceuticals	+2.46%	-0.75%	+2.03%	-7.72%	-48.21%
SBMFF Sino Biopharmaceutical	0.00%	+6.78%	+39.60%	+93.03%	+164.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	3.8859 of 5 stars	2.4	3.0	0.0	4.3	3.2	2.5	0.6
ARGX argenex	2.8506 of 5 stars	2.5	4.0	0.0	0.0	2.5	1.7	1.9
REGN Regeneron Pharmaceuticals	4.9128 of 5 stars	4.4	5.0	1.7	2.3	3.4	1.7	1.9
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.81	Moderate Buy	$392.13	-2.41% Downside
ARGX argenex	3.10	Buy	$736.81	9.35% Upside
REGN Regeneron Pharmaceuticals	2.75	Moderate Buy	$828.86	48.31% Upside
SBMFF Sino Biopharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SBMFF, REGN, ALNY, and ARGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/1/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/1/2025	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$580.00
8/1/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
8/1/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
8/1/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$650.00
8/1/2025	ALNY Alnylam Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$342.00 ➝ $450.00
8/1/2025	ALNY Alnylam Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$403.00 ➝ $550.00
8/1/2025	ALNY Alnylam Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$390.00 ➝ $415.00
8/1/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$333.00 ➝ $395.00
8/1/2025	ALNY Alnylam Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$329.00 ➝ $460.00
8/1/2025	ALNY Alnylam Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$304.00 ➝ $449.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	23.30	N/A	N/A	$0.52 per share	772.69
ARGX argenex	$2.25B	18.31	$2.99 per share	225.66	$90.49 per share	7.45
REGN Regeneron Pharmaceuticals	$14.09B	4.28	$46.81 per share	11.94	$268.50 per share	2.08
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	451.46	N/A	-12.96%	-444.38%	-7.54%	N/A
ARGX argenex	$833.04M	$16.21	34.55	62.10	1.20	40.98%	33.30%	29.52%	N/A
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	14.23	14.70	2.05	31.94%	15.27%	11.93%	N/A
SBMFF Sino Biopharmaceutical	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/13/2025 (Estimated)

Latest SBMFF, REGN, ALNY, and ARGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARGX argenex	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.63%	N/A	8.96%	N/A
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A	N/A	N/A

Latest SBMFF, REGN, ALNY, and ARGX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
ARGX argenex	N/A	7.29	6.68
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
SBMFF Sino Biopharmaceutical	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ARGX argenex	60.32%
REGN Regeneron Pharmaceuticals	83.31%
SBMFF Sino Biopharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
ARGX argenex	2.43%
REGN Regeneron Pharmaceuticals	7.02%
SBMFF Sino Biopharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
REGN Regeneron Pharmaceuticals	15,106	107.97 million	100.39 million	Optionable
SBMFF Sino Biopharmaceutical	25,806	18.76 billion	N/A	Not Optionable

SBMFF, REGN, ALNY, and ARGX Headlines

Recent News About These Companies

Sino Biopharmaceutical Schedules Board Meeting for Interim Results and Dividend Consideration

August 1 at 9:54 AM | msn.com

Sino Biopharmaceutical: Innovation-Driven Growth and Strong Financials Justify Buy Rating

August 1 at 9:01 AM | tipranks.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sets New 12-Month High - Here's What Happened

July 31 at 3:26 PM | marketbeat.com

Sino Biopharmaceutical Advances TQB6411 in Phase I Clinical Trials

July 22, 2025 | tipranks.com

Sino Biopharmaceutical Expands with LaNova Medicines Acquisition Update

July 22, 2025 | tipranks.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Gap Down - Should You Sell?

July 21, 2025 | marketbeat.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Shares Up 23.8% - Still a Buy?

July 18, 2025 | marketbeat.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Hits New 1-Year High - Still a Buy?

July 17, 2025 | marketbeat.com

Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million

July 16, 2025 | msn.com

Sino Biopharmaceutical Acquires Full Stake in LaNova Medicines

July 15, 2025 | tipranks.com

Sino Biopharmaceutical’s New Breast Cancer Treatment Gains Regulatory Acceptance

July 10, 2025 | tipranks.com

Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Large Volume Increase - Time to Buy?

July 2, 2025 | marketbeat.com

Sino Biopharmaceutical Ltd (1177) - Investing.com UK

July 1, 2025 | uk.investing.com

Sino Biopharmaceutical’s LM-108 Gains Breakthrough Therapy Status in China

June 26, 2025 | tipranks.com

Sino Biopharmaceutical Secures Shareholder Approval for Key Resolutions at AGM

June 10, 2025 | tipranks.com

Sino Biopharmaceutical’s Phase III Study Shows Promising Results for NSCLC Treatment

June 3, 2025 | tipranks.com

SBMFF Sino Biopharmaceutical Limited

May 29, 2025 | seekingalpha.com

Sino Biopharmaceutical’s TQB2868 Shows Promise in Pancreatic Cancer Treatment

May 29, 2025 | tipranks.com

Sino Biopharmaceutical Unveils Promising Phase I Data for TQB2102 at ASCO 2025

May 27, 2025 | tipranks.com

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial

May 6, 2025 | msn.com

U.S. FDA Approves China-Produced Cancer Drug

April 28, 2025 | forbes.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBMFF, REGN, ALNY, and ARGX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$401.80 +9.56 (+2.44%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$394.62 -7.18 (-1.79%)

As of 08/1/2025 07:37 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

argenex NASDAQ:ARGX

$673.80 +3.47 (+0.52%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$673.88 +0.09 (+0.01%)

As of 08/1/2025 04:32 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Regeneron Pharmaceuticals NASDAQ:REGN

$558.87 +13.41 (+2.46%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$564.00 +5.13 (+0.92%)

As of 08/1/2025 07:55 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Sino Biopharmaceutical OTCMKTS:SBMFF

$0.95 +0.06 (+6.78%)

As of 07/30/2025 11:33 AM Eastern

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji; cardio-cerebral vascular medicines, such as irbesartan and hydrochlorothiazide tablets under the brand Yilunping and beraprost sodium tablets under the brand Kaina; and biosimilar medicines comprising adalimumab solution for injection under the brand Taibowei. In addition, the company develops oncology drugs, include benmelstobart, D-1553, TQ-B3139, and TQ-B3101; liver disease drugs, such as Lanifibranor and TQA2225/AP025; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time